The DOI matches its Crossref record.
136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with recurrent NSCLC tumours expressing medium or high levels of PD-L1, atezolizumab demonstrated a statistically significant survival advantage in comparison with docetaxel (HR = 0.54; p = 0.014) in a randomized phase II trial (POPLAR).
“Patients with recurrent NSCLC tumours, expressing medium or high levels of PD-L1, Atezolizumab demonstrated a statistically significant survival advantage in comparison with docetaxel (HR = 0.54; p = 0.014) in a randomized phase II trial (POPLAR) [61].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
“Patients with recurrent NSCLC tumours, expressing medium or high levels of PD-L1, Atezolizumab demonstrated a statistically significant survival advantage in comparison with docetaxel (HR = 0.54; p = 0.014) in a randomized phase II trial (POPLAR) [61].”
BackgroundInfluentialGaron, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,239
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L., Chen, J., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 690
Leighl, N. B., Hellmann, M. D., Hui, R., Carcereny, E., Felip, E., Ahn, M., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30500-9 · Cited by 173
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
Hida, T., Velcheti, V., Reckamp, K. L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.011 · Cited by 113
Reck, M., Shankar, G., Lee, A., Coleman, S., McCleland, M. L., Papadimitrakopoulou, V. A., Socinski, M. A., & Sandler, A. B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1701439 · Cited by 62
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Man, J., Millican, J., Mulvey, A., Gebski, V., & Hui, R. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab012 · Cited by 40
Rebuzzi, S. E., Leonetti, A., Tiseo, M., & Facchinetti, F. (2019) · Immunotherapy · doi:10.2217/imt-2019-0107 · Cited by 14
Pollack, M. L. H., Keating, K. N., Wissinger, E., Jackson, L., Sarnes, E., & Cuffel, B. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1847057 · Cited by 14
The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
Pistamaltzian, N. F., Georgoulias, V., & Kotsakis, A. P. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1593828 · Cited by 9
“atezolizumab and docetaxel, respectively [28,29].”
BackgroundDuration of nivolumab for pretreated, advanced non–small‐cell lung cancer
Geier, M., Descourt, R., Corre, R., Leveiller, G., Lamy, R., Goarant, E., Bizec, J., Bernier, C., Quéré, G., Amrane, K., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3120 · Cited by 8
Tuberculose pulmonaire sous traitement par immunothérapie type anti-PD1
Viatgé, T., Mazières, J., Zahi, S., et al. (2020) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2020.06.003 · Cited by 6
Self-citationBaseri, B., Samra, B., Tam, E. L., Chiu, E. J., & Leaf, A. N. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/1816472 · Cited by 6
Aggarwal, H., Ndirangu, K., Winfree, K. B., Muehlenbein, C. E., Zhu, E., Tongbram, V., & Thom, H. H. Z. (2023) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0016 · Cited by 5
The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
Castet, F., Brenes, J., Taberna, M., & Mesı́a, R. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000530 · Cited by 4
Spotlight on atezolizumab and its potential as an oncology agent
Redman, J. M., & Madan, R. A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1483241 · Cited by 4
“For example, in addition to observations from the POPLAR study in NSCLC mentioned above [5], an ORR of 18%, in PD-L1 (1–5% tumor cell positivity) UC, was reported in the phase II study of atezolizumab [12].”
ResultRusso, A., Scilla, K. A., & Rolfo, C. D. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.06.24 · Cited by 4
“Data on pretreated patients are in line with previous reports (14-16), suggesting that approximately 15−20% of patients might derive long-term benefit with ICIs.”
ResultImmune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?
Dingemans, A. C., & Hendriks, L. E. L. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30043-8 · Cited by 2
Fa-qiang, M., Qi, Z., Liao, G., Zhao, L., Su, X., Dong, C., Lu, F., & Sun, Y. (2025) · Medicine · doi:10.1097/md.0000000000041306 · Cited by 1
Authors, V. (2013) · Current Oncology · doi:10.3747/co.20.1906
Shamshad, M. F., Khan, S., Mitra, D., et al. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns8.12824
Metadata
- Authors
- Mazières, J., Park, K., Lewanski, C., Gadgeel, S., Fehrenbacher, L., Rittmeyer, A., Han, J.-Y., Artal-Cortes, A., Braiteh, F., & Vansteenkiste, J.
- Affiliations
- Centre Hospitalier Universitaire de Toulouse (FR)
- Samsung Medical Center (KR)
- Charing Cross Hospital (GB)
- University of Michigan (US)
- Kaiser Permanente Vallejo Medical Center (US)
- National Cancer Center (KR)
- Comprehensive Cancer Centers of Nevada (US)
- KU Leuven (BE)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 13
- Issue
- 4
- Pages
- S79
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2797915357
- Cited by
- 22
- References
- 0
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 11 · 2018: 1
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- atezolizumab, docetaxel, non-small cell lung cancer, second-line therapy, PD-L1 blockade, anti-PD-1 therapy, three-year survival, duration of response, POPLAR trial, overall survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
